A new Collection in Ther Adv Med Oncol examines how biomarker‑driven strategies are shaping lung cancer care across the disease continuum.
Deadline: 29 Jan 2027
buff.ly/RrkerAu
#LungCancer #PrecisionOncology #Biomarkers #MedicalOncology
#ADCs are reshaping breast oncology, alongside new questions on sequencing, biomarkers, and toxicity management. Explore this Ther Adv Med Oncol special collection, guest edited by Paolo Tarantino, MD, and Ilana Schlam, MD.
buff.ly/pZycpW5
#BreastCancer #ADCs #MedicalOncology #OncologyResearch
A new Special Collection in Ther Adv Med Oncol will explore emerging treatment strategies in HR+HER2‑ advanced #BreastCancer, a field marked by rapid therapeutic expansion and ongoing unmet need.
Submission deadline: 14 Dec 2026
buff.ly/Da8ENXI
#HRpositive #HER2negative #MedicalOncology
A real‑world retrospective study in Ther Adv Med Oncol examined the prevalence of HER2‑ultralow disease in HR+/HER2‑negative metastatic breast cancer and reported comparable first‑line chemotherapy outcomes to HER2‑low disease.
buff.ly/Q7JaadR
#BreastCancer #HER2 #MedicalOncology #RealWorldEvidence
Ther Adv Med Oncol announces an open call for a Special Collection on Advances in Clinical Care for Glioblastoma.
We welcome clinically actionable research across the care pathway, from diagnostics to patient‑centered outcomes.
buff.ly/8jRyYqj
#Glioblastoma #NeuroOncology #MedicalOncology
A dual‑center study in Ther Adv Med Oncol evaluated the Systemic Inflammation‑Nutrition Index (SINI) as a predictor of pathological response and relapse‑free survival in locally advanced #GIST treated with neoadjuvant imatinib.
buff.ly/fKecUtx
#Sarcoma #MedicalOncology #TargetedTherapy
Ther Adv Med Oncol announces an open call for a Special Collection on Modern Approaches to Patient Selection in Breast Cancer.
Submissions addressing biomarkers, computational tools, and integrated clinical strategies are welcome.
buff.ly/t6TEH5G
#BreastCancer #MedicalOncology #PrecisionOncology
A dual‑center study evaluates the systemic inflammation–nutrition index (SINI) as a predictor of pathological response and prognosis in locally advanced #GIST treated with neoadjuvant imatinib. A SINI‑based nomogram showed strong discrimination.
buff.ly/pvg142X
#Sarcoma #Imatinib #Biomarkers
🚨 Call for Papers!
Our new Special Collection in Ther Adv Med Onc - Advances in Biomarkers for Genitourinary Cancers - is now open.
🗓 Deadline: 6 Nov 2026
🔗 Submit here: buff.ly/sQgaDWS
#Oncology #GUcancer #Biomarkers #ProstateCancer #BladderCancer #KidneyCancer
Ther Adv Med Oncol: Second‑line mFOLFIRINOX outperformed SOX after gemcitabine+nab‑paclitaxel failure in advanced PDAC (n=113):
• OS 10.4 vs 6.1 mo
• PFS 4.8 vs 2.4 mo
But with higher grade ≥3 AEs.
🔗https://buff.ly/QwPfnx9
#PancreaticCancer #GIOnc
🚨 Call for Papers!
Ther Adv Med Onc invites submissions to our Special Collection on combined immunotherapy for advanced HCC.
🗓 Deadline: 30 Oct 2026
🔗 Submit: buff.ly/e8XA6kU
#HCC #LiverCancer #Immunotherapy #Oncology
Ther Adv Med Oncol:
A review highlights maintenance therapy as a strategy to extend benefit after first‑line anthracyclines in advanced soft tissue #sarcoma.
PLD emerges as a promising continuation option with reduced cardiotoxicity.
Read: 【🔗https://buff.ly/tV2uyCE 】
#STS #Oncology
📣 Call for Papers
Novel Approaches to High‑Risk HER2+ Early‑Stage Breast Cancer - a new Special Collection in Therapeutic Advances in Medical Oncology - is now open.
🗓 Deadline: 4 Dec 2026
🔗 buff.ly/3jv7zmw
A large retrospective cohort shows CLDN18.2 expression does not influence outcomes of first‑line immunochemotherapy in HER2‑negative, pMMR, PD‑L1 CPS≥1 metastatic gastric/GEJ cancer.
🔗 buff.ly/rdAewUh
#GastricCancer #Immunotherapy #CLDN182 #Biomarkers
🚨 Call for Papers – Special Collection: Precision Immuno‑Oncology
We welcome original research, clinical trials, reviews, and real‑world evidence shaping precision cancer care.
Guest Editor: Dr. Peng Luo
🔗 Submission details: buff.ly/fqWNKby
#ImmunoOncology #PrecisionMedicine #Biomarkers
A rev in Ther Adv Med Onc highlights the unique challenges of early breast cancer in young BRCA carriers-covering surveillance, risk‑reducing surgery, PARP‑based therapy, fertility considerations, and survivorship needs. 🔗https://buff.ly/6fj4pvT
#BreastCancer #BRCA #Oncology #YoungPatients
A review in Ther Adv Med Onc summarizes major advances in SCLC: chemo‑IO as standard in ES‑SCLC, durvalumab approved for LS‑SCLC, emerging options for relapse (lurbinectedin, tarlatamab), and evolving biomarkers/transcriptional subtypes. 🔗https://buff.ly/LoHtjYT
#SCLC #LungCancer #Immunotherapy
Real‑world evidence in Ther Adv Med Onc shows nal‑IRI/5‑FU/LV significantly improves OS in pancreatic adenocarcinoma (28.0 vs 18.3 months) despite higher cost (ICER $33,285/LYG). 🔗https://buff.ly/dOq2XvY
#PancreaticCancer #GIOnc #RealWorldEvidence #HealthEconomics
Investigate & optimize hematologic parameters before PARPi (ideal Hb ≥10 g/dL).
Monitor during first 3 months (every 15 days; more often if high‑risk).
Hold PARPi for G2-3 anemia, thrombocytopenia, or G3 neutropenia.
Watch for persistent cytopenias >4 weeks → consider MDS/AML.
French consensus published in Ther Adv Med Onc-provide practical, real‑world guidance to prevent and manage hematologic toxicities from PARPis in metastatic PC-an area of growing need.
🔗 Full article: buff.ly/9fa08rG
#ProstateCancer #mCRPC #PARPInhibitors #Oncology
ctDNA findings from the Ni‑High phase Ib trial: ERBB2 focal amplification and early mMAF decline strongly predict improved outcomes with trastuzumab + nivolumab + chemo in HER2+ aGC.
🔗https://buff.ly/S2kBuFe
#GastricCancer #HER2 #ctDNA
Real‑world, 8‑year multicancer study of lenvatinib shows manageable long‑term use across DTC, AdCC, HCC & EC. Notably, BMI declined during treatment (p=0.045), highlighting the need for closer monitoring in low‑BMI patients.
🔗 buff.ly/Ckygpuz
#Lenvatinib
Review on pregnancy & breast cancer in young women: PrBC vs PPBC distinctions, chemo during pregnancy (incl. taxanes after 1st trimester), POSITIVE trial on ET interruption, and fertility preservation gaps for targeted agents.
🔗 buff.ly/ZDZelh2
#BreastCancer #YWBC
Review: Histologic transformation is a key mechanism of resistance in driver‑positive NSCLC, leading to aggressive SCLC, squamous, or neuroendocrine phenotypes.⬇️ summarize mechanisms and treatment options.
🔗 buff.ly/jJq7xOQ
#NSCLC #LungCancer #Oncology #TargetedTherapy
Among 2798 pts, treatment duration was longer with combinations in both age groups (young 4.1 vs 2.4 mo; elderly 3.9 vs 2.1 mo). TEAEs were similar (≈78%). Leading TRAEs: PPES and hypertension-varying slightly by age group.
Overall: fruquintinib remains a safe option across ages
A Phase IV real‑world analysis examined fruquintinib safety in two under‑studied CRC populations in China: young adults (<50) and the late‑elderly (≥75). Safety events were comparable between age groups, supporting broad applicability.
buff.ly/1Wpdefh
#ColorectalCancer
Key findings:
• mPFS 3.97 mo, OS 20.63 mo
• ORR 8.4%, CBR 33.5%
• Most common AE: peripheral neuropathy (55.2%)
• Higher PN risk with unresolved prior PN or day1–5 infusion schedule
Overall: UTD1 offers a viable option with manageable toxicity.
#CancerResearch #Utidelone
New real‑world evidence on Utidelone (UTD1) for mBC
In a multicenter retrospective study of 270 pts, UTD1, used mainly in combination regimens, showed encouraging effectiveness in heavily pretreated populations.
Link: buff.ly/nayTcuy
#BreastCancer #MBC #Oncology
Grade 3-4 neutropenia: 27.6% with mDCF vs 17.8% with mFOLFOX-6.
Anemia: 9.5% vs 4.8%.
Bottom line: mFOLFOX-6 offers comparable survival with better tolerability-may be the preferred backbone for modern regimens.
#GastricCancer #Oncology #ClinicalTrials #CancerResearch
Doublet vs triplet chemo in advanced gastric & GEJ cancer: which wins?
Multi-center study (493 pts) compared mFOLFOX-6 vs mDCF.
Results: Similar efficacy (ORR ~37%, PFS 6 - 7 mo, OS ~12 mo), but mFOLFOX-6 had fewer grade 3-4 hematologic toxicities.
🔗https://buff.ly/UvoGGkJ